Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury

Spinal Cord Injury Clinical Trial

— CURE-SCI  

Official title:

CURE-SCI. Clinical Utilization of CNS Growth Factor Release in Response to Electrical Stimulation Following Spinal Cord Injury.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01217047
• Other study ID #: NA_00036348
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: October 2010
• Est. completion date: August 2013

Study information

• Verified date: January 2021
• Source: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research is being done to study the effect of Functional Electrical Stimulation (FES) cycling on factors in blood and spinal cord in people with spinal cord injury (SCI).

Description:

FES cycling is a method of applying low level electrical currents to the leg and buttock muscles to cause the weakened or paralyzed muscles to contract and produce a cycling motion of the legs. The FES cycling in this study will be done through a device called the RT300-SL Cycle Ergometer. Although this device has been cleared by the Food and Drug Administration (FDA) for use by individuals with spinal cord injury, we are trying to find out the best way to use it in order to obtain the greatest benefits in an attempt to improve functional recovery.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• History of traumatic spinal cord injury sustained at least 6 months prior

• Complete spinal cord injury at any level American Spinal Injury Association (ASIA) impairment scale A

• No use of functional electrical stimulation within 3 months

• Medically stable, with no recent (1 month or less) inpatient admission for acute medical or surgical issues

• Legally able to make own health care decisions

Exclusion Criteria:

• Cardiovascular disease as defined by previous myocardial infarction, unstable angina, requirement for anti platelet agents, congestive heart failure, or stroke, history of arrhythmia with hemodynamic instability

• Uncontrolled hypertension (resting systolic blood pressure (BP) >160mmHg or diastolic BP >100mmHg consistently)

• Concurrent lower motor neuron disease such as peripheral neuropathy that would exclude lower extremity electrical excitability

• Unstable long bone fractures of the lower extremities

• Subjects who are unwilling to agree to two (2) CSF examinations (lumbar punctures)

• Presence of cardiac pacemaker and/or defibrillator

• Presence of cancer

• History of epileptic seizures

• Subjects having a Stage 2 or greater sacral decubitus ulcer

• Women who are pregnant

• Active drug or alcohol use or dependence

Related Conditions & MeSH terms

• Spinal Cord Injuries
• Spinal Cord Injury
• Wounds and Injuries

Intervention

Device:
• FES Cycling
You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
• Cycling without FES
You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.

Procedure:
• Lumbar puncture
The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).

Behavioral:
• Mood assessment
If you do not already have an account, you will be signed up with "Mood24/7" (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.

Locations

Country	Name	City	State
United States	Kennedy Krieger Institute	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CSF Brain Derived Neurotrophic Factor (BDNF) Level	We will quantify levels of BDNF in the cerebrospinal fluid (CSF) using immunohistochemical quantification methods.	Baseline
Primary	CSF Brain Derived Neurotrophic Factor (BDNF) Level	We will quantify levels of BDNF in the cerebrospinal fluid (CSF) using immunohistochemical quantification methods.	At 3 weeks
Secondary	Mood Assessment	We will assess mood daily on a Likert scale from 1 (low) to 10 (high) using "Mood24/7" (http://www.mood247.com).	3 weeks
Secondary	Spasticity Testing Using the Modified Ashworth Scale (MAS)	The MAS is a widely used neurological rating scale, ranging from 0 (normal) to 5. It measures neurological impairment and disability based on the ratings of an observer or neurologist through structured definitions.	Baseline
Secondary	CSF Growth Factor Quantification	We will quantify levels of neurotrophin-3 (NT3), neurotrophin-4 (NT4), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), and nerve growth factor (NGF) in the cerebrospinal fluid (CSF) using immunohistochemical quantification methods.	Baseline
Secondary	Serum Brain Derived Neurotrophic Factor (BDNF) Level	We will quantify levels of BDNF in the serum/blood using immunohistochemical quantification methods.	Baseline
Secondary	Spasticity Testing Using the Modified Ashworth Scale (MAS)	The MAS is a widely used neurological rating scale, ranging from 0 (normal) to 5. It measures neurological impairment and disability based on the ratings of an observer or neurologist through structured definitions.	At 3 weeks
Secondary	CSF Growth Factor Quantification	We will quantify levels of neurotrophin-3 (NT3), neurotrophin-4 (NT4), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), and nerve growth factor (NGF) in the cerebrospinal fluid (CSF) using immunohistochemical quantification methods.	At 3 weeks
Secondary	Serum Brain Derived Neurotrophic Factor (BDNF) Level	We will quantify levels of BDNF in the serum/blood using immunohistochemical quantification methods.	At 3 weeks